Home » Germany’s Drug Price Proposal Draws Ire of Merck Chairman
Germany’s Drug Price Proposal Draws Ire of Merck Chairman
The German
government’s proposed changes to the nation’s drug-pricing system amount to regulatory overkill and will hurt efforts to bring
drugs to market, Merck Chairman Karl-Ludwig Kley said. The proposed price restructuring would require drugmakers to prove a new drug has a superior cost-benefit
ratio compared with existing treatments as a basis for price negotiations with health insurers.
International Pharmaceutical Regulatory Monitor
International Pharmaceutical Regulatory Monitor
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May